Chrome 2001
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
. .
Chrome 2001
Chrome 2001
Health News Health News
New Technique Protects Tissue Transplant From Rejection: Study
August 13, 2014


WEDNESDAY, Aug. 13, 2014 (HealthDay News) -- A new technique for delivering anti-rejection drugs directly to the site of a tissue graft transplant is effective, lasts for months and is safer than drugs that suppress the entire immune system, a new study indicates.

After a patient receives a tissue graft transplant -- typically on the hand, arm, leg or face -- they start taking drugs to prevent their immune system from rejecting and attacking the new tissue. However, this approach can be toxic and leave patients vulnerable to infection.

The new approach delivers immunosuppressant drugs directly to the site of the tissue graft transplant, and only when they're needed. A hydrogel (jello-like) material is loaded with an immunosuppressant drug called tacrolimus, and this combination is injected under the skin after transplant surgery.

The hydrogel remains inactive until it detects an inflammation/immune response at the transplant site. It then delivers the immunosuppressant drug at the transplant site for months, according to the study published online Aug. 13 in the journal Science Translational Medicine.

"This new approach to delivering immunosuppressant therapy suggests that local delivery of the drug to the grafted tissue has benefits in reducing toxicity, as well as markedly improving therapeutic outcomes, and may lead to a paradigm shift in clinical immunosuppressive therapy in transplant surgery," study co-corresponding author and hydrogel co-developer Jeff Karp, of the division of biomedical engineering at Brigham and Women's Hospital in Boston, said in a hospital news release.

The hydrogel may prove useful in other areas of medicine, according to Karp.

"This safe, controlled-release platform approach functions for over three months from a single injection, and that has broad implications," he said. "Nearly every disease has an inflammatory component. Thus, we believe the materials we have developed could be used for localized treatment of multiple inflammatory diseases."

Karp has a financial interest in a company that is developing hydrogels for skin applications, the news release noted.

More information

The U.S. National Library of Medicine has more about transplant rejection.

Copyright © 2014 HealthDay. All rights reserved.

SOURCE: Brigham and Women's Hospital, news release, Aug. 13, 2014...

More News
InteliHealth .
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
    Print Printer-friendly format    
This website is certified by Health On the Net Foundation. Click to verify.